TransEnterix, Inc., a medical device company, focuses on the development and commercialization of surgical robotic systems. The company has market cap of $343.14 million. The firm offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It currently has negative earnings. It also develops SurgiBot System, a single-port, robotically enhanced laparoscopic surgical platform.
The stock of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a huge mover today! The stock decreased 3.02% or $0.15 during the last trading session, reaching $4.81. About 565,210 shares traded. Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has risen 13.56% since March 13, 2017 and is uptrending. It has underperformed by 3.14% the S&P500.The move comes after 8 months negative chart setup for the $573.24M company. It was reported on Mar, 13 by Barchart.com. We have $4.57 PT which if reached, will make NASDAQ:KERX worth $28.66 million less.
Since October 5, 2017, it had 0 insider buys, and 18 selling transactions for $318,402 activity. 895 shares were sold by Madison Greg, worth $6,435. Shares for $44,064 were sold by Carberry Christine A.. 1,541 Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) shares with value of $7,412 were sold by Adams Brian. The insider Neylan John F. sold 1,541 shares worth $7,412. Holmes Scott A sold 2,830 shares worth $13,612.
Investors sentiment decreased to 1.02 in Q3 2017. Its down 0.48, from 1.5 in 2017Q2. It is negative, as 12 investors sold Keryx Biopharmaceuticals, Inc. shares while 26 reduced holdings. 14 funds opened positions while 43 raised stakes. 75.60 million shares or 1.12% less from 76.46 million shares in 2017Q2 were reported. Baupost Group Ma has 25.79 million shares for 2.28% of their portfolio. Great West Life Assurance Can holds 10,000 shares. Goldman Sachs Grp Incorporated invested in 0% or 708,053 shares. California-based Aperio Gru Ltd Limited Liability Company has invested 0% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Int Grp holds 0% or 54,843 shares in its portfolio. First Republic Invest Incorporated holds 24,653 shares or 0% of its portfolio. New York-based Perceptive Advisors has invested 0.02% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Ameritas Inv Partners Inc holds 0% of its portfolio in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) for 6,152 shares. Clearbridge Invests Limited Liability Company, New York-based fund reported 8,635 shares. Clough Prns Lp reported 0.36% stake. 400,000 are held by Rhenman And Prns Asset Management Ab. State Board Of Administration Of Florida Retirement System invested in 64,782 shares. 281,300 were accumulated by D E Shaw And Co. 10,200 were accumulated by Neuberger Berman Gru Limited Liability. The Ontario – Canada-based Bankshares Of Montreal Can has invested 0% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX).
Among 15 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 6 have Buy rating, 2 Sell and 7 Hold. Therefore 40% are positive. Keryx Biopharmaceuticals had 37 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Buy” rating by Maxim Group given on Thursday, July 27. The stock of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has “Equal-Weight” rating given on Thursday, February 8 by Morgan Stanley. The stock of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has “Buy” rating given on Monday, August 10 by TH Capital. The stock of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) earned “Buy” rating by Roth Capital on Monday, August 10. Raymond James initiated the shares of KERX in report on Wednesday, September 9 with “Market Perform” rating. The rating was maintained by BTIG Research on Thursday, August 6 with “Sell”. On Friday, February 26 the stock rating was downgraded by JP Morgan to “Neutral”. The rating was maintained by Stifel Nicolaus on Friday, February 26 with “Buy”. The stock has “Outperform” rating by Raymond James on Friday, February 26. Stifel Nicolaus maintained Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) rating on Wednesday, November 8. Stifel Nicolaus has “Hold” rating and $5 target.
Analysts await Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) to report earnings on May, 3. They expect $-0.19 EPS, up 9.52% or $0.02 from last year’s $-0.21 per share. After $-0.26 actual EPS reported by Keryx Biopharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -26.92% EPS growth.
Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with renal disease in the United States. The company has market cap of $573.24 million. It markets its lead product Auryxia , an orally available, absorbable, iron medicine for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. It currently has negative earnings. The firm has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan.
Since January 1, 0001, it had 0 insider purchases, and 1 insider sale for $2.21 million activity.
The stock decreased 3.37% or $0.06 during the last trading session, reaching $1.72. About 768,716 shares traded. TransEnterix, Inc. (TRXC) has declined 69.93% since March 13, 2017 and is downtrending. It has underperformed by 86.63% the S&P500.
Sv Health Investors Llc holds 8.18% of its portfolio in TransEnterix, Inc. for 7.55 million shares. Stepstone Group Lp owns 3.03 million shares or 2.87% of their US portfolio. Moreover, Aisling Capital Llc has 2.43% invested in the company for 10.34 million shares. The New York-based Element Capital Management Llc has invested 0.15% in the stock. Masters Capital Management Llc, a Georgia-based fund reported 4.00 million shares.